Babylon’s AI-enabled symptom checker added to recently acquired Higi’s app

Babylon announced Thursday that its AI-enabled symptom monitoring chatbot has now been integrated into Higi’s recently acquired mobile app.

The move comes months after the global digital health company completed the acquisition of Higi in early January. Higi makes FDA-approved kiosks for supermarkets and pharmacies that can monitor health statistics such as blood pressure, heart rate and weight and provide risk assessments. The company also offers an app that tracks the results.

“The integration with Higi is the first opportunity for established platform users to experience Babylon technology,” Babylon CEO and founder Ali Parsa said in a statement.

Linking the Symptom Checker, which is more focused on providing information for consumers’ immediate health needs, with Higi’s long-term view of a patient’s health through risk testing and longitudinal biometric tracking, is a first step toward adding additional resources to the consumer’s toolkit that enable them to proactively and holistically meet their health needs.”


Babylon said the symptom-monitoring chatbot will help users narrow down potential conditions and direct them to health resources.

The integration with Higi will also show how future partners can use Babylon’s tools.

“There is a wealth of knowledge we can provide to consumers when it comes to their health,” Higi CEO Jeff Bennett said in a statement.

“The Symptom Checker is an incredible resource for our users, helping them see the benefit that Babylon technology will bring to our platform, and creating new opportunities for Higi to better serve our partners with value-added solutions that enhance the consumer experience. improve and connect consumers back to the care they need.”


Babylon made two acquisitions in quick succession at the beginning of this year. Shortly after Babylon closed its deal with Higi, the company announced it was… purchased patient engagement tool DayToDay Health.

Originally launched in the UK, Babylon announced its move to the US market at the end of 2019. It went public last year through a merger with a special-purpose acquisition company.

The company announced its fourth quarter and full year financial results earlier this month. While Babylon reported total revenue of $322.9 million for the full year — compared to $79.3 million in 2020 — it also posted a loss of $374.5 million. Babylon attributes some of the loss to one-time costs associated with its public listing, as well as a greater need for resources to support new businesses, public operations and acquisition costs.

“We continue to focus on growth in the United States – [our] value-based care, but also [on] building our software licensing pipeline in 2022 for revenue in “23,” Parsa said during the earnings call.